Kevin Bowrin

882 total citations · 1 hit paper
28 papers, 599 citations indexed

About

Kevin Bowrin is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Internal Medicine. According to data from OpenAlex, Kevin Bowrin has authored 28 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 12 papers in Economics and Econometrics and 10 papers in Internal Medicine. Recurrent topics in Kevin Bowrin's work include Atrial Fibrillation Management and Outcomes (14 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Venous Thromboembolism Diagnosis and Management (10 papers). Kevin Bowrin is often cited by papers focused on Atrial Fibrillation Management and Outcomes (14 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Venous Thromboembolism Diagnosis and Management (10 papers). Kevin Bowrin collaborates with scholars based in Germany, United Kingdom and France. Kevin Bowrin's co-authors include J Brière, Maria Huelsebeck, Rupert Bauersachs, Uwe Zeymer, C. Marre, Mondher Toumi, A. Millier, Craig I Coleman, Pierre Lévy and V. Taieb and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Kevin Bowrin

27 papers receiving 587 citations

Hit Papers

Burden of Coronary Artery Disease and Peripheral Artery D... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
    2019 279 citations Rupert Bauersachs, J Brière et al. Cardiovascular Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Bowrin Germany 10 309 172 97 83 66 28 599
Jonathan Seltzer United States 13 346 1.1× 117 0.7× 80 0.8× 56 0.7× 35 0.5× 30 546
Thomas Bo Jensen Denmark 15 166 0.5× 135 0.8× 65 0.7× 75 0.9× 25 0.4× 40 603
Ranjit More United Kingdom 12 374 1.2× 225 1.3× 76 0.8× 18 0.2× 103 1.6× 63 651
G. Y. H. Lip United Kingdom 13 502 1.6× 59 0.3× 104 1.1× 34 0.4× 37 0.6× 34 805
J. Lau Australia 13 505 1.6× 92 0.5× 91 0.9× 35 0.4× 32 0.5× 34 715
Þórarinn Guðnason Iceland 13 308 1.0× 140 0.8× 43 0.4× 46 0.6× 32 0.5× 27 549
Lucian Petrescu Romania 13 679 2.2× 57 0.3× 66 0.7× 33 0.4× 63 1.0× 42 802
J. Péricles Esteves Brazil 11 206 0.7× 141 0.8× 40 0.4× 22 0.3× 33 0.5× 30 405
Víctor Gil Portugal 14 371 1.2× 114 0.7× 22 0.2× 52 0.6× 52 0.8× 81 690
Michał Peller Poland 17 591 1.9× 110 0.6× 37 0.4× 14 0.2× 73 1.1× 82 827

Countries citing papers authored by Kevin Bowrin

Since Specialization
Citations

This map shows the geographic impact of Kevin Bowrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Bowrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Bowrin more than expected).

Fields of papers citing papers by Kevin Bowrin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Bowrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Bowrin. The network helps show where Kevin Bowrin may publish in the future.

Co-authorship network of co-authors of Kevin Bowrin

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Bowrin. A scholar is included among the top collaborators of Kevin Bowrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Bowrin. Kevin Bowrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Olívia, Stephen Morris, Torben Bjerregaard Larsen, et al.. (2022). Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies. Cardiovascular Therapeutics. 2022. 1–11. 3 indexed citations
2.
Escobar, Carlos, Julio Martí‐Almor, Alejandro Pérez Cabeza, et al.. (2022). Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. PLoS ONE. 17(4). e0266658–e0266658. 9 indexed citations
3.
Blomström‐Lundqvist, Carina, Luis A. Garcı́a Rodrı́guez, Örjan Åkerborg, et al.. (2022). Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis. Journal of Medical Economics. 25(1). 1085–1091. 2 indexed citations
4.
5.
6.
Bowrin, Kevin, J Brière, Laurent Fauchier, et al.. (2020). Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLoS ONE. 15(1). e0225301–e0225301. 10 indexed citations
7.
8.
Soini, Erkki, et al.. (2020). Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Advances in Therapy. 37(7). 3348–3369. 5 indexed citations
9.
Bowrin, Kevin, J Brière, Pierre Lévy, Mondher Toumi, & A. Millier. (2020). Use of real-world evidence in meta-analyses and cost-effectiveness models. Journal of Medical Economics. 23(10). 1053–1060. 5 indexed citations
10.
Bowrin, Kevin, et al.. (2020). Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK. SHILAP Revista de lepidopterología. 8(1). 1782164–1782164. 7 indexed citations
11.
Brière, J, et al.. (2019). PNS322 REVIEW OF METHODOLOGICAL APPROACHES TO ANALYSE LONGITUDINAL UTILITY DATA. Value in Health. 22. S818–S818.
12.
13.
Coleman, Craig I, J Brière, Laurent Fauchier, et al.. (2019). Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. SHILAP Revista de lepidopterología. 7(1). 1574541–1574541. 30 indexed citations
14.
Bauersachs, Rupert, E. Sebastian Debus, Mark R. Nehler, et al.. (2019). A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease. Angiology. 71(4). 303–314. 13 indexed citations
15.
16.
Bowrin, Kevin, J Brière, Pierre Lévy, et al.. (2019). Cost-effectiveness analyses using real-world data: an overview of the literature. Journal of Medical Economics. 22(6). 545–553. 44 indexed citations
17.
Brière, J, Kevin Bowrin, V. Taieb, et al.. (2018). Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. Current Medical Research and Opinion. 34(12). 2125–2130. 27 indexed citations
18.
Brière, J, et al.. (2017). The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective. Journal of Medical Economics. 20(6). 599–605. 8 indexed citations
19.
Sørensen, Rikke, Jannik Langtved Pallisgaard, Berit Jamie Nielsen, Kevin Bowrin, & Christian Torp‐Pedersen. (2016). Abstract 17731: Persistence With Non-vitamin K Oral Anticoagulants And Vitamin K Antagonists Treatment: A Nationwide Study Of Danish Patients With Non-Valvular Atrial Fibrillation. Circulation. 134. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Seltzer Breakdown of academic impact, for papers by Thomas Bo Jensen Breakdown of academic impact, for papers by Ranjit More Breakdown of academic impact, for papers by G. Y. H. Lip Breakdown of academic impact, for papers by J. Lau Breakdown of academic impact, for papers by Þórarinn Guðnason Breakdown of academic impact, for papers by Lucian Petrescu Breakdown of academic impact, for papers by J. Péricles Esteves Breakdown of academic impact, for papers by Víctor Gil Breakdown of academic impact, for papers by Michał Peller
Rankless by CCL
2026